Join the Postmenopausal Symptoms group to help and get support from people like you.
Postmenopausal Symptoms News (Page 5)
Continuous Transdermal Nitroglycerin No Aid for Hot Flashes
FRIDAY, June 9, 2023 – Uninterrupted transdermal nitroglycerin (NTG) therapy does not offer sustained benefit for hot flashes, according to a study published online June 5 in JAMA Internal Medicine....
Risk of Hypertension Up With Use of Oral Estrogen-Only Hormone Therapy
THURSDAY, June 8, 2023 – For postmenopausal women using estrogen-only hormone therapy (HT), oral estrogen-only HT use is associated with increased risk of hypertension, according to a study...
Could a Nitroglycerin Patch Ease Hot Flashes?
TUESDAY, June 6, 2023 – A new study on using nitroglycerin patches to help women with frequent hot flashes caused by menopause has delivered mixed results. The benefits of wearing these patches — l...
One Form of Menopause Hormone Therapy Might Raise Blood Pressure
MONDAY, June 5, 2023 – Women who use estrogen to ease menopause symptoms may see their blood pressure rise — but the way they take the hormone may determine that, a large new study suggests. The s...
Catching Extra Sleep on Weekends Tied to Lower Risk for Hyperuricemia
WEDNESDAY, May 24, 2023 – Weekend catch-up sleep among postmenopausal women is associated with a decreased prevalence of hyperuricemia, according to a study published online May 16 in Menopause. Soo...
FDA Approves First Nonhormonal Drug, Veozah, to Ease Menopause Hot Flashes
MONDAY, May 15, 2023 – The U.S. Food and Drug Administration on Friday approved the first nonhormonal medication aimed at easing menopause hot flashes. The new pill, called Veozah (fezolinetant), is...
FDA Approves First Nonhormonal Drug to Ease Menopause Hot Flashes
SATURDAY, May 13, 2023 – The U.S. Food and Drug Administration on Friday approved the first nonhormonal medication aimed at easing menopause hot flashes. The new pill, called Veozah (fezolinetant),...
FDA Approves Osphena (ospemifene) for Moderate to Severe Vaginal Dryness Due to Menopause
BLAINVILLE, QC, January 29, 2019 – Duchesnay Inc., a pharmaceutical company specializing in women’s health, announced today that the FDA has approved its supplemental New Drug Application (sNDA) see...
FDA Approves Bijuva (estradiol and progesterone) Capsules for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause
BOCA RATON, Fla.--(BUSINESS WIRE)--Oct. 29, 2018-- TherapeuticsMD, Inc, an innovative women’s healthcare company, today announced that the United States Food and Drug Administration (FDA) has a...
FDA Approves Intrarosa (prasterone) for Postmenopausal Women Experiencing Dyspareunia
November 17, 2016 – The U.S. Food and Drug Administration approved Intrarosa (prasterone) to treat women experiencing moderate to severe pain during sexual intercourse (dyspareunia), a symptom of...
Noven Receives FDA Approval of a New Indication with a New Dose for Minivelle
Miami, FL and New York, NY, – September 24, 2014 – Noven Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved a new indication with a new dose of...
FDA Approves Brisdelle - First Non-Hormonal Treatment for Hot Flashes Associated with Menopause
June 28, 2013 --The U.S. Food and Drug Administration today approved Brisdelle (paroxetine) to treat moderate to severe hot flashes (vasomotor symptoms) associated with menopause. Brisdelle, which...
FDA Approves Osphena for Postmenopausal Women Experiencing Dyspareunia
February 26, 2013 – The U.S. Food and Drug Administration today approved Osphena (ospemifene) to treat women experiencing moderate to severe dyspareunia (pain during sexual intercourse), a symptom...
FDA Medwatch Alert: Compounded Menopause Hormone Therapy Drugs
[Posted 01/10/2008] FDA informed healthcare professionals and patients that the Agency sent letters warning seven pharmacy operations that the claims they make about the safety and effectiveness of...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Atrophic Vaginitis, Menopausal Disorders
Related drug support groups
gabapentin, Paxil, paroxetine, estradiol, Premarin, Estrace, desvenlafaxine